# Vernal Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vernal-biosciences

- Industry: Biotechnology
- Headquarters: Burlington, US
- Website: www.vernal.bio
- Total disclosed funding: $41M
- Latest round: Series A (Jun 14, 2023)
- Investors on record: 6

## About

Founded in 2020 and based in Vermont, US, Vernal Biosciences, Inc. operates as a manufacturer of mRNA and LNP-mRNA, platform process development technologies on a transactional basis. In June 2023, Vernal Biosciences, Inc. raised USD 20 million in venture funding co-led by Ampersand Capital Partners and Charles River Laboratories, with participation from Dynamk Capital and Vermont Center for Emerging Technologies. As of 2023, the company is led by CEO, Christian Cobaugh.

Vernal Biosciences' services and products include mRNA sequence design, custom mRNA, GMP mRNA manufacturing, LPN formulated mRNA, and catalog mRNA products such as reporter gene mRNA, genome editing mRNA, gene replacement mRNA, and antigen mRNA.

The company plans to use the June 2023 funding to finish the construction of its GMP factory, support expanded mRNA and LNP manufacturing, and increase its capabilities to support cGMP manufacturing.

## Funding rounds

- Series A, Jun 14, 2023, $20M — Ampersand, Charles River Laboratories, Dynamk Capital, Vermont Center for Emerging Technologies
- Series A, Jun 2, 2022, $21M — Ampersand, Charles River Laboratories, Dynamk Capital, Alloy Therapeutics, Inc., DNA TwoPointO Inc.

## Investors

- Ampersand (https://capitalatlas.ai/funds/ampersand) — Series A
- Charles River Laboratories — Series A
- Dynamk Capital (https://capitalatlas.ai/funds/dynamk-capital) — Series A
- Alloy Therapeutics, Inc. — Series A
- DNA TwoPointO Inc. — Series A
- Vermont Center for Emerging Technologies — Series A